Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference

Amylyx Pharmaceuticals, Inc. today announced that two abstracts detailing next steps in the development of the Company’s investigational antisense oligonucleotide , AMX0114, for the potential...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Japan ,Massachusetts ,United States ,Orlando ,Florida ,Canada , ,Muscular Dystrophy Association ,Amylyx Pharmaceuticals Inc ,Linkedin ,Exchange Commission ,Nasdaq ,Twitter ,Amylyx Pharmaceuticals ,Scientific Conference ,Next Steps ,Critical Effector ,Axonal Degeneration ,Findings From ,Pharmacodynamic Study ,Sodium Phenylbutyrate ,Participants With Amyotrophic Lateral Sclerosis ,Safety Information ,Enterohepatic Circulation Disorders ,Pancreatic Disorders ,Patients Sensitive ,High Sodium ,Private Securities Litigation Reform Act ,Amylyx United States Securities ,Amylyx Quarterly Report ,Markets ,